Kalaris Therapeutics Statistics
Total Valuation
KLRS has a market cap or net worth of $102.78 million. The enterprise value is -$676,359.
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026, before market open.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KLRS has 23.79 million shares outstanding. The number of shares has increased by 898.75% in one year.
| Current Share Class | 23.79M |
| Shares Outstanding | 23.79M |
| Shares Change (YoY) | +898.75% |
| Shares Change (QoQ) | +21.95% |
| Owned by Insiders (%) | 6.02% |
| Owned by Institutions (%) | 17.91% |
| Float | 7.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.45 |
| P/TBV Ratio | 1.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.19, with a Debt / Equity ratio of 0.02.
| Current Ratio | 12.19 |
| Quick Ratio | 12.03 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -66.60% and return on invested capital (ROIC) is -44.48%.
| Return on Equity (ROE) | -66.60% |
| Return on Assets (ROA) | -27.97% |
| Return on Invested Capital (ROIC) | -44.48% |
| Return on Capital Employed (ROCE) | -46.82% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.20M |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +66.15% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +66.15% |
| 50-Day Moving Average | 5.05 |
| 200-Day Moving Average | 6.68 |
| Relative Strength Index (RSI) | 41.10 |
| Average Volume (20 Days) | 82,155 |
Short Selling Information
The latest short interest is 762,669, so 3.21% of the outstanding shares have been sold short.
| Short Interest | 762,669 |
| Short Previous Month | 801,523 |
| Short % of Shares Out | 3.21% |
| Short % of Float | 10.56% |
| Short Ratio (days to cover) | 10.54 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -47.63M |
| Pretax Income | -44.10M |
| Net Income | -44.10M |
| EBITDA | n/a |
| EBIT | -47.63M |
| Earnings Per Share (EPS) | -$2.18 |
Full Income StatementBalance Sheet
The company has $97.22 million in cash and $1.41 million in debt, giving a net cash position of $103.46 million or $4.35 per share.
| Cash & Cash Equivalents | 97.22M |
| Total Debt | 1.41M |
| Net Cash | 103.46M |
| Net Cash Per Share | $4.35 |
| Equity (Book Value) | 68.56M |
| Book Value Per Share | 2.98 |
| Working Capital | 90.39M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$42.51 million and capital expenditures -$200,000, giving a free cash flow of -$42.71 million.
| Operating Cash Flow | -42.51M |
| Capital Expenditures | -200,000 |
| Depreciation & Amortization | 23,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -42.71M |
| FCF Per Share | -$1.80 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |